In conclusion, targeted therapies directed against mutant IDH1 have opened a new therapeutic avenue for patients with IHCC with IDH1 mutations, and the FDA recently approved ivosidenib for previously-treated IDH1-mutated advanced cholangiocarcinoma. Here, IDH1 is linked to cholangiocarcinoma.